Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without Transarterial Chemoembolization as First-line Treatment for Advanced Hepatocellular Carcinoma With Vascular Invasions

NCT06881446 is registered in ClinicalTrials.gov with Zhongda Hospital as lead sponsor.

NCT NCT06881446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06881446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without Transarterial Chemoembolization as First-line Treatment for Advanced Hepatocellular Carcinoma With Vascular Invasions
Lead sponsor
Zhongda Hospital
Phase
Observational
Overall status
Completed
Start date
June 1, 2018
Completion date
September 30, 2025
Enrollment
2,651 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)